

Edward Pan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3676961/publications.pdf>

Version: 2024-02-01

44
papers

864
citations

567281

15
h-index

501196

28
g-index

45
all docs

45
docs citations

45
times ranked

1590
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary central nervous system sarcomas in adults: A systematic review. <i>Clinical Neurology and Neurosurgery</i> , 2022, 214, 107127.	1.4	4
2	Post-Traumatic Gliomas in Adults: Review of the Case Reports and Studies. <i>Canadian Journal of Neurological Sciences</i> , 2022, , 1-8.	0.5	2
3	BIMG-09. GLUTAMINE AND GLYCINE BY MR SPECTROSCOPY IDENTIFY AGGRESSIVE GLIOMAS. <i>Neuro-Oncology Advances</i> , 2021, 3, i2-i3.	0.7	0
4	Spectral fitting strategy to overcome the overlap between $^{2}\alpha$ -hydroxyglutarate and lipid resonances at 2.25 ppm. <i>Magnetic Resonance in Medicine</i> , 2021, 86, 1818-1828.	3.0	7
5	A Modified Nucleoside 6-Thio- $^{2}\alpha$ -Deoxyguanosine Exhibits Antitumor Activity in Gliomas. <i>Clinical Cancer Research</i> , 2021, 27, 6800-6814.	7.0	10
6	Reversibly Modulating the Blood-Brain Barrier by Laser Stimulation of Molecular-Targeted Nanoparticles. <i>Nano Letters</i> , 2021, 21, 9805-9815.	9.1	49
7	Spinal Cord Pilocytic Astrocytoma With FGFR1-TACC1 Fusion and Anaplastic Transformation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 283-285.	1.7	6
8	Review of rituximab in primary CNS lymphoma. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116649.	0.6	3
9	Occurrence of Glioma in Pregnant Patients: An Institutional Case Series and Review of the Literature. <i>Anticancer Research</i> , 2020, 40, 3453-3457.	1.1	6
10	Basis for Immunotherapy for Treatment of Meningiomas. <i>Frontiers in Neurology</i> , 2020, 11, 945.	2.4	27
11	Predictors of prognosis of synchronous brain metastases in small-cell lung cancer patients. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 531-539.	3.3	16
12	NRG/RTOG 1122: A phase 2, double-blind, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. <i>Cancer</i> , 2020, 126, 2821-2828.	4.1	25
13	Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness. <i>Neuro-Oncology</i> , 2020, 22, 1018-1029.	1.2	37
14	In vivo MRS measurement of $^{2}\alpha$ -hydroxyglutarate in patient-derived IDH mutant xenograft mouse models versus glioma patients. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 1152-1160.	3.0	11
15	Safety Profile of Maintenance Obinutuzumab in Patients with Primary CNS Lymphoma in Complete Response. <i>Blood</i> , 2020, 136, 12-12.	1.4	1
16	NIMG-24. GLYCINE AND GLUTAMINE BY MR SPECTROSCOPY ARE IMAGING BIOMARKERS OF GLIOMA AGGRESSIVENESS. <i>Neuro-Oncology</i> , 2020, 22, ii152-ii152.	1.2	0
17	Adult Primary Peripheral PNET/Ewing's Sarcoma of the Cervical and Thoracic Spine. <i>Anticancer Research</i> , 2019, 39, 4463-4465.	1.1	6
18	Seizures in glioma patients: An overview of incidence, etiology, and therapies. <i>Journal of the Neurological Sciences</i> , 2019, 404, 80-85.	0.6	30

#	ARTICLE	IF	CITATIONS
19	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 5799-5807.	7.0	166
20	H3 K27M Mutations in Thalamic Pilocytic Astrocytomas with Anaplasia. <i>World Neurosurgery</i> , 2019, 124, 87-92.	1.3	6
21	An Adult Patient With Rare Primary Intracranial Alveolar Rhabdomyosarcoma. <i>Anticancer Research</i> , 2019, 39, 3067-3070.	1.1	4
22	NIMG-13. GLYCINE IS A METABOLIC BIOMARKER OF MALIGNANCY IN GLIOMAS: IN VIVO MAGNETIC RESONANCE SPECTROSCOPY STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi164-vi164.	1.2	0
23	NCMP-07. SECONDARY ADRENAL INSUFFICIENCY IN ADULT PATIENTS WITH GLIOMA: A CASE SERIES. <i>Neuro-Oncology</i> , 2019, 21, vi180-vi180.	1.2	1
24	NIMG-08. 2-HYDROXYGLUTARATE MAGNETIC RESONANCE SPECTROSCOPY IN BRAINSTEM TUMOR PATIENTS IN VIVO. <i>Neuro-Oncology</i> , 2019, 21, vi163-vi163.	1.2	0
25	3D high-resolution imaging of 2-hydroxyglutarate in glioma patients using DRAG-EPSI at 3T in vivo. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 795-802.	3.0	9
26	Spinal Pleomorphic Xanthoastrocytoma With a QKI-RAF1 Fusion. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 10-14.	1.7	8
27	Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 302-311.	1.7	60
28	PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 159-162.	1.3	15
29	Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients. <i>Magnetic Resonance in Medicine</i> , 2018, 79, 1851-1861.	3.0	30
30	PATH-59. THALAMIC GLIOMAS WITH H3 K27M MUTATION. A CASE SERIES AND LITERATURE REVIEW. <i>Neuro-Oncology</i> , 2018, 20, vi171-vi171.	1.2	0
31	HOUT-06. PATTERN OF LOW FIELD INTENSITY RECURRENCE IN HIGH-GRADE GLIOMAS FOLLOWING TUMOR TREATMENT FIELD THERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi114-vi114.	1.2	0
32	RARE-37. OCCURRENCE OF GLIOMA IN PREGNANT PATIENTS: INSTITUTIONAL CASE SERIES AND REVIEW OF THE LITERATURE. <i>Neuro-Oncology</i> , 2018, 20, vi243-vi243.	1.2	0
33	NIMG-76. POST-GADOLINIUM 3-DIMENSIONAL SPATIAL, SURFACE, AND STRUCTURAL CHARACTERISTICS OF GLIOBLASTOMAS DIFFERENTIATE PSEUDOPROGRESSION FROM TRUE TUMOR PROGRESSION. <i>Neuro-Oncology</i> , 2018, 20, vi192-vi193.	1.2	0
34	Brainstem Glioblastoma Multiforme in a Patient with NF1. <i>Anticancer Research</i> , 2018, 38, 4897-4900.	1.1	8
35	Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogession from true tumor progression. <i>Journal of Neuro-Oncology</i> , 2018, 139, 731-738.	2.9	12
36	In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 936-944.	3.0	40

#	ARTICLE	IF	CITATIONS
37	Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. <i>Journal of Neuro-Oncology</i> , 2017, 133, 183-192.	2.9	30
38	Measurement of glycine in healthy and tumorous brain by triple-echo focusing MRS at 3T <i>in vivo</i> . <i>NMR in Biomedicine</i> , 2017, 30, e3747.	2.8	9
39	A TNF- α -JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. <i>Nature Neuroscience</i> , 2017, 20, 1074-1084.	14.8	82
40	Detection of 2-hydroxyglutarate in brain tumors by triple-echo focusing MR spectroscopy at 3T <i>in vivo</i> . <i>Magnetic Resonance in Medicine</i> , 2017, 78, 40-48.	3.0	28
41	Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. <i>Nature Communications</i> , 2017, 8, 1913.	12.8	62
42	Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 571-579.	2.9	39
43	Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. <i>Journal of Neuro-Oncology</i> , 2014, 119, 413-420.	2.9	2
44	Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. <i>Anticancer Research</i> , 2011, 31, 4537-43.	1.1	12